Listing 11.12 Myasthenia Gravis in 2026: How SSA Decides SSDI Claims Under Paragraph A Bulbar and Neuromuscular Weakness Despite Therapy, Paragraph B Myasthenic Crisis Requiring Non-Invasive or Mechanical Ventilation, and Paragraph C Marked Physical Plus Marked Mental Limitation

By Anthony Albert, Benefits Research Director, Disability Exchange · Updated July 1, 2026 · SSA Blue Book Section 11.00 Neurological (Adult)

Myasthenia gravis (MG) is the classic autoimmune neuromuscular junction disorder. Antibodies attack the acetylcholine receptor (AChR), the muscle-specific tyrosine kinase (MuSK), or the low-density lipoprotein receptor-related protein 4 (LRP4) at the neuromuscular junction. The result is fluctuating weakness that worsens with activity and improves with rest. MG affects about 20 per 100,000 people in the United States, with two peaks: young women in their 20s and 30s (often AChR positive), and older men in their 60s and 70s (often thymoma-associated).

SSA classifies MG under Listing 11.12 in the Section 11.00 Neurological Adult body system. Unlike ALS (which qualifies as a Compassionate Allowance on diagnosis), 11.12 requires meeting a specific paragraph A, B, or C severity test. This guide walks all three paragraphs of 11.12 with the verbatim text, the 2026 diagnostic picture (AChR and MuSK antibody assays, repetitive nerve stimulation, single-fiber EMG), the standard treatment ladder (pyridostigmine, prednisone, mycophenolate, azathioprine, IVIG, plasma exchange, rituximab, and the newer targeted biologics efgartigimod, rozanolixizumab, ravulizumab, eculizumab, and zilucoplan), and how myasthenic crisis triggers Paragraph B. Two worked Massachusetts and Florida cases close the file.

If you have MG and your symptoms are not controlled despite treatment, or you have had a crisis, you may meet 11.12. See If You Qualify.

What 11.12 Actually Says

Here is the verbatim text of Listing 11.12 from the SSA Blue Book Section 11.00 Neurological (Adult):

The listing offers three independent paths. You have to meet only one. Paragraph A is the motor-function-extreme-limitation path. Paragraph B is the crisis path. Paragraph C is the marked-plus-marked path.

Paragraph A: Two-Extremity Motor Dysfunction With Extreme Limitation for at Least 3 Months

Paragraph A borrows the same 11.00D1 disorganization of motor function framework used in Listing 11.08 spinal cord disorders and Listing 11.09 multiple sclerosis. Two extremities have to be affected. That can be both arms, both legs, or one arm and one leg. The limitation has to be extreme under 11.00D2. And it has to persist for at least 3 consecutive months despite prescribed treatment.

11.00D1 Disorganization of Motor Function

Motor function is disorganized when it is impaired by weakness, incoordination, or difficulty controlling movement. In MG, this presents as fluctuating fatigable weakness. A patient may look strong at the start of an exam and be markedly weak after a few minutes of repetitive testing. The examiner has to document the fluctuation across the visit.

11.00D2 Extreme Limitation

Extreme limitation means you are unable, or nearly unable, to perform the specific function. For 11.12 Paragraph A the three functions listed are: (a) stand up from a seated position, (b) balance while standing or walking, or (c) use the upper extremities. "Nearly unable" is the operative language. A patient who can rise from a chair only with both hands pushing off, or who cannot rise at all without assistance, has an extreme limitation of standing up. A patient who cannot walk without holding on to a wall or another person for balance has an extreme limitation of balance.

11.00K Despite Prescribed Treatment

Section 11.00K controls the treatment adherence requirement. The claimant has to be on treatment or have documented reasons for not being on it. Standard first-line therapy for MG is pyridostigmine (Mestinon). Second-line adds prednisone or another immunosuppressant. The record should show that the claimant is either taking these medications and still symptomatic, or that they have side effects or contraindications that prevent full treatment.

Paragraph B: Myasthenic Crisis Requiring Mechanical Ventilation, Three Times in 12 Months

Paragraph B is the crisis path. Myasthenic crisis under 11.00E4 is defined as an acute worsening of MG requiring mechanical ventilation. The listing requires three crises within a 12-month window despite adherence to treatment.

What Counts as Mechanical Ventilation

Mechanical ventilation includes both invasive ventilation (via endotracheal tube or tracheostomy) and non-invasive positive pressure ventilation (BiPAP) delivered acutely for respiratory failure. A patient who was intubated in the ICU for hypercapnic respiratory failure due to MG meets the criteria. A patient who was placed on BiPAP in the ICU for the same reason also meets, per 11.00E4 language that includes non-invasive ventilation when used to manage acute respiratory failure.

How Common Is MG Crisis in 2026

Historically about 15 to 20 percent of MG patients had at least one crisis during their disease course. With modern treatment and access to advanced biologics, that number has fallen but is still meaningful. Crisis triggers include infection (most common), aspiration pneumonia, surgery, pregnancy, medication changes (especially fluoroquinolones, aminoglycosides, macrolides, telithromycin, beta blockers in high doses, and certain anesthetic agents), and rapid steroid taper.

A patient with three crises in 12 months despite pyridostigmine, prednisone, and IVIG or plasma exchange is a treatment-refractory phenotype. That is a strong Paragraph B file.

Paragraph C: Marked Physical Plus Marked Mental Limitation

Paragraph C is the two-area marked test. The claimant has to have marked limitation in physical functioning (11.00G3a) AND marked limitation in one of the four mental functioning areas (11.00G3b). Both markings have to persist despite prescribed treatment.

11.00G2 Marked Limitation

Marked limitation means the impairment seriously limits your ability to function independently, appropriately, and effectively on a sustained basis. It is less severe than extreme but more than moderate.

11.00G3a Physical Functioning

Marked physical limitation in MG covers difficulty with balance, standing, walking, using hands and arms, seeing due to ptosis or diplopia, or maintaining posture. In generalized MG, most patients have marked physical limitation once the disease is progressive or refractory.

11.00G3b Mental Functioning

The four areas are:

1. Understanding, remembering, or applying information. Includes learning new material, following instructions, and performing tasks that require memory or reasoning.
2. Interacting with others. Includes working with supervisors, coworkers, and the public. Sustaining conversations, handling criticism, and cooperating.
3. Concentrating, persisting, or maintaining pace. Includes staying focused during a task, working at a consistent pace, and completing tasks on time. Fatigue in MG erodes this significantly.
4. Adapting or managing oneself. Includes managing routine changes, tolerating stress, being aware of hazards, and maintaining personal care.

MG is associated with fatigue-related cognitive symptoms (sometimes called "brain fog") and with depression at rates estimated in the 15 to 30 percent range across published cohorts. The marked mental limitation can be established by treating psychiatrist notes, formal neuropsychological testing showing impaired processing speed or working memory, or documented failure to maintain concentration during workday-length tasks.

Diagnostic Picture: What Confirms MG

SSA does not require a specific diagnostic test to meet 11.12, but the diagnosis has to be established. The 2026 workup typically includes:

Antibody Testing

• AChR (acetylcholine receptor) antibody. Positive in 80 to 85 percent of generalized MG and 50 to 60 percent of ocular MG. Three types: binding, blocking, and modulating. Binding antibody is the standard first test.
• MuSK (muscle-specific kinase) antibody. Positive in 5 to 10 percent of MG. MuSK-positive patients often have prominent bulbar and neck weakness, are frequently female, and respond less well to pyridostigmine and thymectomy but respond well to rituximab.
• LRP4 (low-density lipoprotein receptor-related protein 4) antibody. Positive in a small percentage of seronegative patients.
• Anti-titin and anti-ryanodine receptor. Associated with thymoma. Screening for these in older patients or in patients with mediastinal masses is standard.

Electrophysiology

• Repetitive nerve stimulation (RNS). A decrement of the compound muscle action potential (CMAP) of greater than 10 percent between the first and fourth or fifth response at 2 to 3 Hz stimulation is diagnostic. Facial, ulnar, and spinal accessory nerves are commonly tested. Sensitivity is moderate (about 50 to 70 percent).
• Single-fiber EMG (SFEMG). The most sensitive test. Measures jitter (variability in inter-potential interval between two muscle fibers innervated by the same motor unit). Sensitivity 90 to 95 percent for generalized MG. Requires specialized equipment and an experienced electromyographer.

Imaging

• Chest CT. To screen for thymoma. About 10 to 15 percent of MG patients have thymoma. Thymectomy is indicated for thymoma and can be considered for AChR-positive MG without thymoma in patients under 60.

Bedside and Pharmacologic Tests

• Ice pack test. A cold compress applied to a ptotic eyelid for 2 minutes improves lid position in MG. Simple bedside screen.
• Edrophonium (Tensilon) test. Rarely used in 2026 due to safety concerns. Replaced by antibody and electrophysiology.

2026 Treatment Ladder

MG treatment has expanded dramatically since 2017 with the approval of complement inhibitors and FcRn antagonists. The 2026 treatment ladder is:

First Line: Symptomatic

• Pyridostigmine (Mestinon). Acetylcholinesterase inhibitor. Dose usually 60 mg every 4 to 6 hours. Extended release available (Mestinon Timespan 180 mg). Side effects: cramps, diarrhea, sweating, increased secretions.

Second Line: Immunosuppression

• Prednisone. The workhorse. Effective in 70 to 80 percent of patients but limited by long-term side effects (weight gain, diabetes, osteoporosis, cataracts, avascular necrosis).
• Mycophenolate mofetil (CellCept). Steroid-sparing. Typical dose 1000 to 1500 mg twice daily.
• Azathioprine (Imuran). Alternative steroid-sparing agent. Requires TPMT testing before starting.
• Tacrolimus. Third-line calcineurin inhibitor.

Rapid Rescue

• Plasma exchange (PLEX). Removes circulating antibodies. Effect within 1 to 2 weeks. Used for crisis and pre-thymectomy.
• Intravenous immunoglobulin (IVIG). Similar timeline. Standard 2 g/kg divided over 2 to 5 days.

Targeted Biologics (Newer Options)

• Rituximab (Rituxan). Anti-CD20 monoclonal. Off-label but used widely, especially for MuSK-positive MG. Two 1000 mg IV infusions given 2 weeks apart, repeated every 6 to 12 months.
• Eculizumab (Soliris). Complement C5 inhibitor. FDA-approved 2017 for AChR-positive generalized MG refractory to other therapies. Requires meningococcal vaccination.
• Ravulizumab (Ultomiris). Longer-acting complement C5 inhibitor. FDA-approved 2022 for AChR-positive generalized MG. Every 8-week dosing.
• Zilucoplan (Zilbrysq). Subcutaneous complement C5 inhibitor. FDA-approved October 2023 for AChR-positive generalized MG. Self-administered daily.
• Efgartigimod (Vyvgart). FcRn antagonist that lowers circulating IgG including autoantibodies. FDA-approved December 2021 for AChR-positive generalized MG. IV infusion in cycles.
• Efgartigimod alfa/hyaluronidase-qvfc (Vyvgart Hytrulo). Subcutaneous formulation. FDA-approved June 2023.
• Rozanolixizumab (Rystiggo). Another FcRn antagonist. FDA-approved June 2023 for AChR-positive and MuSK-positive generalized MG. Subcutaneous cyclical dosing.

Thymectomy

The MGTX trial (2016) established that thymectomy plus prednisone is superior to prednisone alone for AChR-positive non-thymomatous MG in patients under 65. Thymectomy is standard of care for thymoma at any age. Long-term follow-up data from MGTX-EXT continued to support the benefit at 5 years.

How DDS Reads an MG File

The strongest 11.12 files include:

1. Diagnostic confirmation. Positive antibody test (AChR, MuSK, or LRP4) or positive SFEMG or positive RNS with decrement.
2. Longitudinal treatment record. Documentation of pyridostigmine, prednisone, and at least one steroid-sparing agent tried. If the patient is on advanced biologics (efgartigimod, rituximab, eculizumab, etc.), that establishes treatment refractoriness.
3. Functional evidence. For Paragraph A: neurology exam with two-extremity extreme weakness on repetitive testing, documented across at least 3 months. For Paragraph B: three ICU or ED records with hospital admission for myasthenic crisis with ventilation. For Paragraph C: neurology exam with marked physical limitation plus neuropsychological testing or psychiatry notes with marked mental limitation in one domain.

Bulbar MG Presentation

Bulbar-predominant MG deserves special attention because it triggers Paragraph B risk. Bulbar symptoms include:

• Dysarthria that worsens with talking (nasal voice, hypernasality).
• Dysphagia that worsens through a meal.
• Chewing fatigue.
• Head drop from neck flexor weakness.
• Dyspnea, especially supine.

Bulbar patients aspirate. They need speech-language pathology evaluation, video fluoroscopic swallow study (VFSS), and often modified diets. Aspiration pneumonia is a common trigger for crisis. Bulbar MG patients should have pulmonary function testing (FVC, MIP, MEP) at each visit. FVC below 20 mL/kg or MIP less than 30 cmH2O signals impending crisis.

Ocular MG

About 15 to 20 percent of MG patients have ocular-only disease with ptosis and diplopia but no generalized weakness. Pure ocular MG rarely meets 11.12 because the motor function and mental function requirements are hard to satisfy with eye symptoms alone. However, most patients with ocular MG generalize within 2 to 3 years. If your MG is currently ocular but you have new limb or bulbar symptoms, get re-tested.

Worked Example: Jennifer, 44, Cambridge, Massachusetts

Jennifer, a 44-year-old former biotech researcher in Cambridge, MA, developed progressive ptosis and diplopia in early 2024. Neurology at Mass General diagnosed AChR-positive generalized MG in May 2024 after positive binding antibody (12.5 nmol/L, reference less than 0.4), positive repetitive nerve stimulation showing 32 percent decrement in the right ulnar nerve, and single-fiber EMG showing markedly increased jitter.

Jennifer started pyridostigmine 60 mg every 4 hours and prednisone 60 mg daily. Chest CT showed a thymic remnant without thymoma. She underwent robotic thymectomy in September 2024. Post-thymectomy she had continued generalized weakness. Mycophenolate 1000 mg BID was added in November 2024. In February 2025 she had an MG crisis triggered by influenza. She was intubated in the ICU for 6 days, treated with plasma exchange (5 sessions), and discharged on higher-dose prednisone plus mycophenolate.

She had a second crisis in June 2025 (triggered by a urinary tract infection treated with ciprofloxacin, a fluoroquinolone that can worsen MG). Intubated for 3 days. Plasma exchange. Started on efgartigimod in July 2025 in cycles.

She had a third crisis in November 2025 (triggered by aspiration pneumonia). BiPAP in the ICU for 4 days without intubation, plus plasma exchange.

Jennifer filed for SSDI in December 2025. Her neurologist at Mass General signed an HA-1152 documenting three crises within 12 months (February, June, November 2025) despite pyridostigmine, prednisone, mycophenolate, thymectomy, and efgartigimod. Two of the crises required intubation. One required BiPAP.

DDS allowed the claim in March 2026 under Listing 11.12 Paragraph B. The decision cited three myasthenic crises within a 12-month window under 11.00E4, adherence to treatment under 11.00K, and refractoriness despite thymectomy and advanced biologics. Onset was set at February 2025 (first crisis). Back pay covered 12 months.

Worked Example: Miguel, 66, Orlando, Florida

Miguel, a 66-year-old retired mechanic in Orlando, developed progressive proximal leg weakness, difficulty rising from chairs, and dysphagia in mid-2024. Chest CT in September 2024 showed a 4.5 cm anterior mediastinal mass. Neurology workup at Orlando Health confirmed AChR-positive MG (binding antibody 8.4 nmol/L) with associated thymoma. He underwent transsternal thymectomy in November 2024. Pathology confirmed WHO type B2 thymoma. Started on pyridostigmine and prednisone. Adjuvant radiation to the thymic bed was given for capsular invasion.

Post-thymectomy Miguel continued to have severe generalized weakness. He could not rise from a seated position without both arms pushing off. He could not walk more than 20 feet without holding on to walls or furniture. His grip strength dropped to 12 kg on the right (from an age-matched norm of 35 kg). Sit-to-stand testing showed he required both hands to push up in 5 out of 5 attempts, with one attempt requiring assistance from his wife.

Neurology added mycophenolate in January 2025. Weakness persisted through follow-up visits in February, April, June, and September 2025 despite the medication combination. In October 2025 the neurologist added ravulizumab (Ultomiris) infusions after documenting inadequate response to standard therapy.

Miguel filed for SSDI in November 2025. His neurology note from September 2025 documented extreme limitation in standing up from a seated position, extreme limitation in balance while standing or walking, and marked weakness of both upper extremities, persisting for more than 3 months despite pyridostigmine, prednisone, mycophenolate, and thymectomy.

DDS allowed the claim in February 2026 under Listing 11.12 Paragraph A. The decision cited two-extremity motor dysfunction with extreme limitation in the ability to stand up from a seated position and to balance while standing, persisting for more than 3 months despite prescribed treatment under 11.00D1, 11.00D2, and 11.00K. Onset was set at the date of his thymectomy, November 2024. Back pay covered 15 months.

For related Section 11 listings see our deep dives on Listing 11.08 spinal cord disorders, Listing 11.09 multiple sclerosis, and Listing 11.10 ALS.

State Pages

If you are filing in Massachusetts, see our Massachusetts SSDI page. If you are filing in Florida, see our Florida SSDI page. Other state pages: Texas, California, New York, Pennsylvania, Ohio.

What to Include in the File at Application

• Neurology consultation notes with the MG diagnosis and treatment history.
• Positive AChR, MuSK, or LRP4 antibody test result.
• Repetitive nerve stimulation report or single-fiber EMG report if antibodies negative.
• Chest CT (thymoma screening).
• Medication list with dates started and doses.
• ICU or ED records for any myasthenic crises with ventilation.
• Sit-to-stand testing, grip strength, timed walking, and functional exam documentation.
• Pulmonary function testing (FVC, MIP, MEP) if bulbar or respiratory symptoms.
• Neuropsychological testing or psychiatry notes if pursuing Paragraph C.
• HA-1152 medical source statement from the treating neurologist matching the target paragraph.

Step 5 RFC Fallback

If the listing is not quite met, the Step 5 analysis for MG has to account for fluctuating fatigue. A claimant who can look strong for a 30-minute exam but cannot sustain function across an 8-hour workday requires an RFC that includes:

• Sedentary or less exertional level.
• Unscheduled breaks throughout the day (predictably associated with symptom worsening).
• Off-task time exceeding 10 percent of the workday due to fatigable weakness.
• Absence 2 or more days per month due to disease flares or treatment infusions.
• Environmental restrictions (avoid heat, humidity, infection exposure, workplaces where medication timing cannot be controlled).

A vocational expert testifying at hearing will typically confirm that these restrictions eliminate the residual occupational base.

Frequently Asked Questions

If you have MG and your daily function is significantly impaired despite treatment, the paperwork is worth doing. See If You Qualify.